CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Genitourinary Cancer » Prostate Cancer

ONCOLOGY. Vol. 17 No. 1
 

Commentary (Hemstreet): Management of Sexual Dysfunction After Prostate Brachytherapy

The Merrick/Wallner/Butler Article Reviewed

By George P. Hemstreet III, MD, PhD1 | January 1, 2003
1Professor, Department of Surgery; Chief, Section of Urologic Surgery, Nebraska Medical Center, Omaha, Nebraska

Erectile dysfunction is associated with brachytherapy, conformal radiation, or radical surgery (perineal or retropubic) for the control of localized prostate cancer. The article by Merrick, Wallner, and Butler focuses specifically on the effect of brachytherapy on erectile dysfunction and impotency.

Over the past decade, investigators have defined the neuroanatomy and biochemical pathways that regulate erectile function. Specifically, our growing knowledge of the pathophysiology and biochemical role of nitrous oxide (a potent biologic mediator of vascular smooth muscle relaxation) and the function of testosterone has resulted in new approaches for the pharmacologic manipulation of erectile dysfunction.[ 1] In addition, enhanced transdermal and systemic delivery of drugs portends improved therapeutic management in the future.

(MORE: Management of Sexual Dysfunction After Prostate Brachytherapy)

Elucidation of the functional genomics associated with erectile dysfunction also heralds the introduction of new therapeutic modalities. Treatment is facilitated because sexual dysfunction is no longer a "closed closet" topic, especially given mass media advertising for drugs such as sildenafil(Drug information on sildenafil) (Viagra). Mass media communication has also boosted the dialog between sexual partners and their physicians. This has improved marital relations and the treatment of patients in the earlier stages of erectile dysfunction.

Nevertheless, because all treatment modalities for the control of localized prostate cancer are nearly equal in efficacy, a cardinal question for most patients centers on the risk of impotency and other quality-oflife (QOL) issues following treatment  with the various modalities. Discussion of these issues by Merrick et al is timely.

Advances in Radiation Therapy

The historical development of brachytherapy reflects multiple technical advances. Gold brachytherapy for the management of prostate cancer was pioneered by Flocks at the University of Iowa and Carlton at Baylor College of Medicine in Houston. Suprapubic and transperineal brachytherapy with iodine-125 seeds were later reinvestigated by Whitmore in the 1970s.

In recent years, precise ultrasound seed placement and the science of radiation physics have yielded therapeutic results similar to those achieved with surgery for localized prostate cancer in small glands, when results are compared at 13 years in nonrandomized studies. Conformal radiation alone or in combination with external-beam irradiation, and quality control with the B-mode Acquired Target (BAT) ultrasound system, offer another alternative alone or in combination with adjunctive hormonal ablation.[2] Thus, precise evaluation of erectile function and other QOL issues such as rectal bleeding, incontinence, and response to pharmacologic enhancement following therapy are needed to compare the results of all treatment modalities alone or in combination.

Surgical Advances

From a surgical perspective, nervesparing radical prostatectomy reflects an improved understanding of the male neuroanatomy facilitated by the landmark efforts of Lepor[3] and others, who clearly delineated the anatomy of the neurovascular bundle. The neurovascular bundle runs parallel to the urethra and decussates along the prostate capsule and the lateral aspects of the gland. Consequently, prostate cancer arising at the apex or periphery of the gland in proximity to the neurovascular bundle requires sacrifice of the erectile nerves to attain local cancer control in some cases. If both nerves are transected, impotency is certain. If one nerve is spared, the potency is 46% at 5 years, and if both nerves are spared, this increases to 61%.

FIGURE 1
Figure 1: Development of an Erection
Development of an Erection

Treatment of patients postsurgically has improved erectile function. For example, sildenafil, a type 5 phosphodiesterase inhibitor, indirectly potentiates the effects of nitrous oxide on sinusoidal smooth muscle by causing increased intracellular cyclic guanosine monophosphate (GMP) in the corpora cavernosal bodies, resulting in smooth muscle relaxation and penile tumescence (see Figure 1).[4]

However, more precise methods are needed to determine whether nerve-sparing surgery is indicated for one or both nerves. It is frequently difficult to determine the proximity of the neoplasm to the capsule, and pathologic assessment is not always accurate because of surgical trauma. Robotically controlled laparoscopy provides improved optical resolution and decreases surgical trauma but eliminates tactile clues-a potential advantage of open surgery.

Improved Technology

FIGURE 2
Figure 2: Two-Dimensional Image of a Prostate
Two-Dimensional Image of a Prostate

Advances in computer analysis of contrast-enhanced transrectal color Doppler ultrasonography (TRCDUS) for prostate neovascularity may assist in defining the limits of the tumor prior to deciding whether to sacrifice one or both nerves during the preoperative evaluation and serve as a guide for biopsy and rebiopsy in the future.[ 5,6] Based on the images shown in Figure 2, the three-dimensional image in Figure 3 was reconstructed via neural net analysis of radiofrequency waves generated by conventional ultrasound machines.[7] Eventually, real-time imaging and collection of data such as this should be possible.

FIGURE 3
Figure 3: Reconstructed Three-Dimensional Image
Reconstructed Three-Dimensional Image

A clear logical advantage of conformal radiation or seed implants is the anatomic preservation of the neurovascular bundle without the need for nerve resection and sural nerve grafting. However, if surgery is selected and a unilateral or bilateral nerve resection is required, the option of a sural nerve graft (a small nerve near the ankle) performed by the urologist and plastic surgeon facilitates nerve regeneration and erectile function. The autonomic nerves are easily identified using an electric nerve probe, and the ends are carefully marked at the base of the penis and adjacent to the bladder. Usually, the sural nerve graft is 5 to 7 cm in length, depending on the gap left following resection of the nerve. Once harvested, the graft is rotated 180o to promote nerve regeneration, and the nerve is sewn in place without tension. Nerve regeneration occurs in 6 to 12 months and, thus, requires long-term QOL assessment and supportive erections to maintain the health of the erectile tissues.

Pharmacologic Advances

This article illustrates that there is a need to evaluate each of the treatment modalities and their effect on erectile dysfunction, both early and late in course of the prescribed therapy. Once evaluated, pharmacologic manipulation with drugs such as sildenafil or newer agents such as vardenafil(Drug information on vardenafil) and cialis potentiate the effect of nitric oxide-activated GMP by inhibiting breakdown of the enzyme. The newer inhibitors on the horizon have more   rapid activation, longer duration, and potentially fewer side effects.

From a basic science perspective, it remains to be determined if there are growth factors that might improve nerve regeneration in patients reenervated with sacral nerve grafts, or in those receiving radiation therapy or chemotherapy. The molecular aspects of peripheral nerve regeneration with growth factors is an active area of research, involving both in vitro and in vivo experiments to evaluate nerve regeneration and erectile function.

Conclusions

Improved physical properties of radiation therapy and more precise methods of delivery (such as BAT) continue to enhance this modality. Ultrasound imaging has enabled more precise placement of iodine-125 and palladium-103 seeds as well as better control of conformal radiation, reducing intratreatment error and subjecting adjacent organs such as the rectum to less radiation. Radiation therapy provides the distinct advantage of leaving the neurovascular bundle intact with the potential for additional pharmacologic manipulation and improved quality of life with preserved erectile function. All treatment modalities have early and late undesirable effects on erectile dysfunction. The critical issue, however, is the long-term outcome following the initial 6- to 9-month evaluation.

Validation of erectile dysfunction with QOL questionnaires will assist in delineating the best multimodality approach for preserving erectile function and for minimizing the morbidity associated with the treatment of prostate cancer. Further basic science related to nerve regeneration may improve all treatment outcomes that currently result in decreased erectile dysfunction.

However, because current estimates of therapeutic effectiveness are similar for each of the various treatment options, larger controlled clinical trials will be necessary to clearly establish the best primary treatment for the control of the disease and the preservation of erectile function. Unfortunately, controlled trials comparing radiation to surgery have been difficult to complete and have neither incorporated QOL issues nor standardized surgical techniques or the delivery of radiation therapy.

Articles such as this one by Merrick et al put these issues in perspective and are likely to affect the design and completion of future clinical trials.

Financial Disclosure: The author has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

This commentary refers to the following article

Management of Sexual Dysfunction After Prostate Brachytherapy



GREGORY S. MERRICK, MD,KENT E. WALLNER, MD,WAYNE M. BUTLER, PhD


1. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376, 1980.
2. Butler WM, Merrick GS, Dorsey AT, et al: Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 48:1575-1582, 2000.
3. Lepor H, Gregerman M, Crosby R, et al: Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: A detailed anatomical study of the adult male pelvis. J Urol 133:207-212, 1985.
4. Zippe CD, Jhaveri FM, Klein EA, et al: Viagra after radical prostatectomy. Urology 55:241-245, 2000.
5. Lattarnzi J, McNeeley S, Pinover W, et al: A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys 43:719-725, 1999.
6. Strohmeyer D, Frauscher F, Klauser A, et al: Contrast-enhanced transrectal color doppler ultrasonography (TRCDUS) for assessment of angiogenesis in prostate cancer. Anticancer Res 21:2907-2913, 2001.
7. Balaji KC, Fair WR, Feleppa EJ, et al: Role of advanced 2 and 3-dimensional ultrasound for detecting prostate cancer. J Urol 168:2422-2425, 2002.


 
RELATED CONTENT

Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
May 20, 2013
New AUA Guidelines for Prostate Cancer Screening
May 17, 2013
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
May 17, 2013
Radium-223 Gets Early FDA Nod for Bone Mets in Castration-Resistant Prostate Cancer
May 16, 2013
Rising PSA Level in a 46-Year-Old Man
ONCOLOGY,  May 15, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Rising PSA Level in a 46-Year-Old Man
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Prostate Cancer
Evidence on Prostate Cancer
Guidelines on Prostate Cancer
Patient Education on Prostate Cancer
Clinical Trials on Prostate Cancer
Practical Articles on Prostate Cancer
Research and Reviews on Prostate Cancer
All "Prostate Cancer" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy